Atrial Fibrillation (AF) is the most common arrhythmia, which can lead to stroke, peripheral embolization, heart failure and other unfavorable outcomes. While the incidence of AF among the general population has been found to be at about 2.3%-3.4%, this registers a significant increase in patients with pulmonary disease, critical illness or systemic inflammatory response syndrome, with devastating clinical impact. A number of recent epidemiological studies have established a greater risk of AF and new-onset AF among patients with COVID-19, though the results have been quite inconsistent. The literature available thus far has indicated that AF or new-onset AF can have a substantial association with the worst outcomes, viz., mortality, in patients with COVID-19.

Apart from the recent development of COVID-19 and its effect on AF, other factors that increase the risk of this condition include growing worldwide prevalence of obesity and heart diseases. The rise in the number of AF cases is fueling the market for treating this disease, though at the same time posing a crushing burden on the economies of several countries because of the high treatment cost involved.

Research Findings & Coverage

  • Global Atrial Fibrillation market is analyzed in this report with respect to treatment type/sub-type, end-user facilities
  • The study exclusively analyzes the market size of each treatment type/sub-type and end-user facility of Atrial Fibrillation by all major geographic regions/countries
  • Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
  • Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
  • Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
  • Revolutionary Catheter Ablation Technologies for AF Take Centerstage
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled – 19
  • The industry guide includes the contact details for 70 companies

Product Outline
The report analyzes the market for the following key treatment types/sub-types of Atrial Fibrillation:

  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Electric Cardioversion
    • High Intensity Focused Ultrasound (HIFU)
    • Maze Surgery
    • Other Ablation Treatments
  • Pharmacological Treatment
    • Blood Thinners
    • Heart Rate Drugs
    • Heart Rhythm Drugs

End-User Facilities of Atrial Fibrillation analyzed in this study comprise the following:

  • Ambulatory Surgical Centers
  • Cardiac Centers
  • Hospitals

Analysis Period, Units and Growth Rates

  • The report reviews, analyzes and projects the global Atrial Fibrillation market for the period 2018-2027 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2022 through 2027 with a special focus on y-o-y growth for 2019, 2020 and 2021

Geographic Coverage

  • North America (The United States, Canada and Mexico)
  • Europe (France, Germany, Italy, the United Kingdom and Rest of Europe)
  • Asia-Pacific (China, India, Japan and Rest of Asia-Pacific)
  • Rest of World